{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:52:14Z","timestamp":1793397134003,"version":"4.5.0"},"reference-count":78,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Groupe de recherche de l\u2019Institut Claudius Regaud","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"French government","award":["Idex 2012"],"award-info":[{"award-number":["Idex 2012"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,7,31]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian adenocarcinoma (OVAD) frequently metastasizes to the peritoneal cavity and manifests by the formation of ascites, which constitutes a tumor-promoting microenvironment. In the peritoneal cavity, two developmentally, phenotypically and functionally distinct macrophage subsets, immunocompetent large peritoneal macrophages (LPM) and immunosuppressive small peritoneal macrophages (SPM), coexist. Because peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) is a critical factor participating in macrophage differentiation and cooperates with CCAAT\/enhancer binding protein \u03b2 (C\/EBP\u03b2), a transcription factor essential for SPM-to-LPM differentiation, PPAR\u03b3 could be also involved in the regulation of SPM\/LPM balance and could be a promising therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To evaluate the 15(S)-hydroxyeicosatetraenoic acid (HETE), a PPAR\u03b3 endogenous ligand, impact on ovarian tumor growth, we intraperitoneally injected 15(S)-HETE into a murine ovarian cancer model. This experimental model consists in the intraperitoneally injection of ID8 cells expressing luciferase into syngeneic C57BL\/6 female mice. This ID8 orthotopic mouse model is a well-established experimental model of end-stage epithelial OVAD. Tumor progression was monitored using an in vivo imaging system. Peritoneal immune cells in ascites were analyzed by flow cytometry and cell sorting. To determine whether the impact of 15(S)-HETE in tumor development is mediated through the macrophages, these cells were depleted by injection of liposomal clodronate. To further dissect how 15(S)-HETE mediated its antitumor effect, we assessed the tumor burden in tumor-bearing mice in which the PPAR\u03b3 gene was selectively disrupted in myeloid-derived cells and in mice deficient of the recombination-activating gene\n                      <jats:italic>Rag2<\/jats:italic>\n                      . Finally, to validate our data in humans, we isolated and treated macrophages from ascites of individuals with OVAD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show, in the murine experimental model of OVAD, that 15(S)-HETE treatment significantly suppresses the tumor growth, which is associated with the differentiation of SPM into LPM and the LPM residency in the peritoneal cavity. We demonstrate that C\/EBP\u03b2 and GATA6 play a central role in SPM-to-LPM differentiation and in LPM peritoneal residence through PPAR\u03b3 activation during OVAD. Moreover, this SPM-to-LPM switch is associated with the increase of the effector\/regulatory T-cell ratio. Finally, we report that 15(S)-HETE attenuates immunosuppressive properties of human ovarian tumor-associated macrophages from ascites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Altogether, these results promote PPAR\u03b3 as a potential therapeutic target to restrain OVAD development and strengthen the use of PPAR\u03b3 agonists in anticancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-007031","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:16:04Z","timestamp":1692191764000},"page":"e007031","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["PPAR\u03b3 activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression"],"prefix":"10.1136","volume":"11","author":[{"given":"M\u00e9lissa","family":"Prat","sequence":"first","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Coulson","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Blot","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefroy","family":"Jacquemin","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Romano","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Renoud","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"AlaEddine","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Le Naour","sequence":"additional","affiliation":[{"name":"UMR1037 Centre de Recherche en Canc\u00e9rologie de Toulouse (CRCT), Universit\u00e9 de Toulouse, INSERM, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Authier","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna Chirine","family":"Rahabi","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaddouj","family":"Benmoussa","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Salon","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lissa","family":"Parny","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Ferron","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Couderc","sequence":"additional","affiliation":[{"name":"UMR1037 Centre de Recherche en Canc\u00e9rologie de Toulouse (CRCT), Universit\u00e9 de Toulouse, INSERM, Toulouse, France"},{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7781-3323","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Coste","sequence":"additional","affiliation":[{"name":"RESTORE Research Center, Universit\u00e9 de Toulouse, INSERM-1301, CNRS-5070, EFS, ENVT, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2025100301481691000_11.8.e007031.1","first-page":"E174","article-title":"Worldwide incidence and mortality of ovarian cancer and human development index (HDI): GLOBOCAN sources and methods 2018","volume":"62","author":"Khazaei","year":"2021","journal-title":"J Prev Med Hyg"},{"key":"2025100301481691000_11.8.e007031.2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2015.06.017","article-title":"Why have ovarian cancer mortality rates declined? part I","volume":"138","author":"Sopik","year":"2015","journal-title":"Gynecologic Oncology"},{"key":"2025100301481691000_11.8.e007031.3","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0032"},{"key":"2025100301481691000_11.8.e007031.4","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200003000-00006"},{"key":"2025100301481691000_11.8.e007031.5","first-page":"447","article-title":"Pelvic inflammatory disease and the risk of epithelial ovarian cancer","volume":"4","author":"Risch","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025100301481691000_11.8.e007031.6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00256"},{"key":"2025100301481691000_11.8.e007031.7","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjz090"},{"key":"2025100301481691000_11.8.e007031.8","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-4-30","article-title":"Monocyte\/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease","volume":"4","author":"Wang","year":"2006","journal-title":"J Transl Med"},{"key":"2025100301481691000_11.8.e007031.9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2025100301481691000_11.8.e007031.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4005"},{"key":"2025100301481691000_11.8.e007031.11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jlb.64.3.275","article-title":"Tumor-induced immune dysfunction: the macrophage connection","volume":"64","author":"Elgert","year":"1998","journal-title":"J Leukoc Biol"},{"key":"2025100301481691000_11.8.e007031.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"2025100301481691000_11.8.e007031.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"2025100301481691000_11.8.e007031.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2011"},{"key":"2025100301481691000_11.8.e007031.15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mc.22750","article-title":"Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-\u039aB activation","volume":"57","author":"Cho","year":"2018","journal-title":"Mol Carcinog"},{"key":"2025100301481691000_11.8.e007031.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4375"},{"key":"2025100301481691000_11.8.e007031.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3777"},{"key":"2025100301481691000_11.8.e007031.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.02.008"},{"key":"2025100301481691000_11.8.e007031.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00127","article-title":"Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues","volume":"5","author":"Van Overmeire","year":"2014","journal-title":"Front Immunol"},{"key":"2025100301481691000_11.8.e007031.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194637"},{"key":"2025100301481691000_11.8.e007031.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.04.004"},{"key":"2025100301481691000_11.8.e007031.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.12.001"},{"key":"2025100301481691000_11.8.e007031.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915000107"},{"key":"2025100301481691000_11.8.e007031.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00225","article-title":"Revisiting Mouse peritoneal Macrophages: heterogeneity, development, and function","volume":"6","author":"Cassado","year":"2015","journal-title":"Front Immunol"},{"key":"2025100301481691000_11.8.e007031.25","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.57.3.361"},{"key":"2025100301481691000_11.8.e007031.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.016"},{"key":"2025100301481691000_11.8.e007031.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300581"},{"key":"2025100301481691000_11.8.e007031.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403424111"},{"key":"2025100301481691000_11.8.e007031.29","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0802907","article-title":"Regulation of Ppargamma activity during Adipogenesis","volume":"29 Suppl 1","author":"Farmer","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"2025100301481691000_11.8.e007031.30","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01344-13"},{"key":"2025100301481691000_11.8.e007031.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01677.x"},{"key":"2025100301481691000_11.8.e007031.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.11.004"},{"key":"2025100301481691000_11.8.e007031.33","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7801","article-title":"LRH-1 mediates anti-inflammatory and antifungal phenotype of IL-13-activated Macrophages through the PPAR\u03b3 ligand synthesis","volume":"6","author":"Lef\u00e8vre","year":"2015","journal-title":"Nat Commun"},{"key":"2025100301481691000_11.8.e007031.34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0213"},{"key":"2025100301481691000_11.8.e007031.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0583"},{"key":"2025100301481691000_11.8.e007031.36","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07565"},{"key":"2025100301481691000_11.8.e007031.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65117-6"},{"key":"2025100301481691000_11.8.e007031.38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2741\/4021","article-title":"PPAR gamma, bioactive lipids, and cancer progression","volume":"17","author":"Robbins","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2025100301481691000_11.8.e007031.39","first-page":"5671","article-title":"A new ligand for the peroxisome proliferator-activated receptor-\u0393 (PPAR-\u0393), Gw7845, inhibits rat mammary carcinogenesis","volume":"59","author":"Suh","year":"1999","journal-title":"Cancer Res"},{"key":"2025100301481691000_11.8.e007031.40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3990"},{"key":"2025100301481691000_11.8.e007031.41","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh160"},{"key":"2025100301481691000_11.8.e007031.42","unstructured":"Niu S , Cui B , Huang J , et al . PPAR\u03b3 is correlated with prognosis of epithelial ovarian cancer patients and affects tumor cell progression in vitro. 2017. Available: https:\/\/www.semanticscholar.org\/paper\/PPAR%CE%B3-is-correlated-with-prognosis-of-epithelial-in-Niu-Cui\/1ef90c884388dab19b083b16290beb90ea2176f8"},{"key":"2025100301481691000_11.8.e007031.43","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/159415","article-title":"Clinical use of Ppargamma ligands in cancer","volume":"2008","author":"Hatton","year":"2008","journal-title":"PPAR Res"},{"key":"2025100301481691000_11.8.e007031.44","doi-asserted-by":"crossref","unstructured":"Reddy AT , Lakshmi SP , Reddy RC . PPAR\u03b3 as a novel therapeutic target in lung cancer. PPAR Res 2016:8972570. doi:10.1155\/2016\/8972570","DOI":"10.1155\/2016\/8972570"},{"key":"2025100301481691000_11.8.e007031.45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2018.01.020","article-title":"Anti-Leukemic effects of PPAR\u03b3 ligands","volume":"418","author":"Ryu","year":"2018","journal-title":"Cancer Lett"},{"key":"2025100301481691000_11.8.e007031.46","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/cncr.20574","article-title":"Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma","volume":"101","author":"Reichle","year":"2004","journal-title":"Cancer"},{"key":"2025100301481691000_11.8.e007031.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180329197"},{"key":"2025100301481691000_11.8.e007031.48","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.585"},{"key":"2025100301481691000_11.8.e007031.49","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.12"},{"key":"2025100301481691000_11.8.e007031.50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000714","article-title":"PPAR\u03b3 controls dectin-1 expression required for host antifungal defense against Candida albicans","volume":"6","author":"Gal\u00e8s","year":"2010","journal-title":"PLoS Pathog"},{"key":"2025100301481691000_11.8.e007031.51","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2013.04.010","article-title":"The C-type lectin receptors Dectin-1, MR, and Signr3 contribute both positively and negatively to the macrophage response to Leishmania Infantum","volume":"38","author":"Lef\u00e8vre","year":"2013","journal-title":"Immunity"},{"key":"2025100301481691000_11.8.e007031.52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004335","article-title":"Oncolytic Orf virus licenses NK cells via Cdc1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","volume":"10","author":"van Vloten","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100301481691000_11.8.e007031.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35524-7","article-title":"Adipose tissue is a source of regenerative cells that augment the repair of skeletal muscle after injury","volume":"14","author":"Sastourn\u00e9-Arrey","year":"2023","journal-title":"Nat Commun"},{"key":"2025100301481691000_11.8.e007031.54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/bjc.1985.36","article-title":"Percoll density gradient separation of cells from human malignant effusions","volume":"51","author":"Hamburger","year":"1985","journal-title":"Br J Cancer"},{"key":"2025100301481691000_11.8.e007031.55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.22.12953"},{"key":"2025100301481691000_11.8.e007031.56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30787-x","article-title":"Characterization of human peritoneal monocyte\/macrophage Subsets in homeostasis: phenotype, Gata6, Phagocytic\/oxidative activities and Cytokines expression","volume":"8","author":"Ruiz-Alcaraz","year":"2018","journal-title":"Sci Rep"},{"key":"2025100301481691000_11.8.e007031.57","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2016.10.052"},{"key":"2025100301481691000_11.8.e007031.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-520619"},{"key":"2025100301481691000_11.8.e007031.59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48741-w","article-title":"Serpinb2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages","volume":"9","author":"Schroder","year":"2019","journal-title":"Sci Rep"},{"key":"2025100301481691000_11.8.e007031.60","first-page":"541","article-title":"15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium","volume":"145","author":"Takata","year":"1994","journal-title":"Am J Pathol"},{"key":"2025100301481691000_11.8.e007031.61","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191869","article-title":"Tissue-resident Macrophages in Omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J Exp Med"},{"key":"2025100301481691000_11.8.e007031.62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3892\/ijmm.2015.2230","article-title":"Ovarian cancer stem cells induce the M2 polarization of Macrophages through the PPAR\u03b3 and NF-\u039aB pathways","volume":"36","author":"Deng","year":"2015","journal-title":"Int J Mol Med"},{"key":"2025100301481691000_11.8.e007031.63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002548","article-title":"S100A4 enhances Protumor macrophage polarization by control of PPAR-\u0393-dependent induction of fatty acid oxidation","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100301481691000_11.8.e007031.64","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0612"},{"key":"2025100301481691000_11.8.e007031.65","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423168","article-title":"PPAR\u03b3-activation increases intestinal M1 Macrophages and mitigates formation of Serrated adenomas in mutant KRAS mice","volume":"7","author":"Gutting","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100301481691000_11.8.e007031.66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.15.8806"},{"key":"2025100301481691000_11.8.e007031.67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025192","article-title":"Anticancer effects of 15D-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on Sirt1 and HDAC","volume":"6","author":"de Jong","year":"2011","journal-title":"PLoS One"},{"key":"2025100301481691000_11.8.e007031.68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbrc.2011.02.052","article-title":"PPAR\u03b3 ligands induce growth inhibition and apoptosis through P63 and P73 in human ovarian cancer cells","volume":"406","author":"Kim","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"2025100301481691000_11.8.e007031.69","first-page":"3344","article-title":"Ligand for peroxisome Proliferator-activated receptor \u0393 (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo","volume":"58","author":"Kubota","year":"1998","journal-title":"Cancer Res"},{"key":"2025100301481691000_11.8.e007031.70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.1.237"},{"key":"2025100301481691000_11.8.e007031.71","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/431763","article-title":"Peroxisome Proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling Cascade in cancer","volume":"2008","author":"Giaginis","year":"2008","journal-title":"PPAR Res"},{"key":"2025100301481691000_11.8.e007031.72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1128"},{"key":"2025100301481691000_11.8.e007031.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.02.025"},{"key":"2025100301481691000_11.8.e007031.74","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04457"},{"key":"2025100301481691000_11.8.e007031.75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.prostaglandins.2017.01.002","article-title":"Alox15 as a suppressor of inflammation and cancer: lost in the link","volume":"132","author":"Tian","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2025100301481691000_11.8.e007031.76","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1595-y"},{"key":"2025100301481691000_11.8.e007031.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.07.033"},{"key":"2025100301481691000_11.8.e007031.78","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9098-3"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:48:31Z","timestamp":1759481311000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/jitc-2023-007031"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007031","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}